Calendar of Events Mobile Version

9:00 a.m.: Marc Tessier-Lavigne, Ph.D., president, Carson Family Professor and head, Laboratory of Brain Development and Repair, The Rockefeller University, Welcome Remarks

9:10 a.m.: Andrew D. Luster, M.D., Ph.D., chief, division of rheumatology, allergy and immunology, Massachusetts General Hospital; Persis, Cyrus and Marlow B. Harrison Professor of Medicine, Harvard Medical School, What Do Chemokines Have to Do With Fc Receptors?

9:40 a.m.: Michel C. Nussenzweig, M.D., Ph.D., senior physician, The Rockefeller University Hospital, Zanvil A. Cohn and Ralph M. Steinman Professor and head, Laboratory of Molecular Immunology, The Rockefeller University; investigator, Howard Hughes Medical Institute, Antibody Responses in Humans and Mice

10:10 a.m.: Tomohiro Kurosaki, M.D., Ph.D., professor, laboratory of lymphocyte differentiation, WPI Immunology Frontier Research Center, Osaka University, Instructive Selection of Germinal Center B Cells into the Memory Compartment

10:40 a.m.: Alan A. Aderem, Ph.D., affiliate professor, department of medicine and department of immunology, University of Washington School of Medicine; president and director, Seattle Biomedical Research Institute, A Systems Approach to Dissecting Immunity

11:10 a.m.: Fubin Li, Ph.D., principal investigator, department of microbiology and immunology, Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Immunology, Fc of Agonistic Antibodies

11:40 a.m.: Sir Marc Feldmann, Ph.D., M.B.B.S., professor and head, Kennedy Institute of Rheumatology, University of Oxford, Beyond Anti-TNF Therapy for Rheumatoid Arthritis: Can We Get Closer to a Cure?

1:30 p.m.: Toshiyuki Takai, Ph.D., professor, Laboratory of Experimental Immunology, Tohoku University School of Medicine, Regulatory Receptors Characterizing Peripheral B-Lineage Cells in SLE

2:00 p.m.: Mikael Karlsson, Ph.D., senior researcher and associate professor, department of microbiology, tumor and cell biology, Karolinska Institutet, Reprogramming Tumor-associated Macrophages by Antibody Targeting

2:30 p.m.: Roger M. Perlmutter, M.D., Ph.D., executive vice president and president of Merck Research Laboratories, Merck & Co., Inc., Immune-mediated Control of Malignant Disease

3:00 p.m.; Robert M. Anthony, Ph.D., principal investigator, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital; assistant professor of medicine, Harvard Medical School, Glycan Regulation of Immunoglobulins

3:45 p.m.: Tadatsugu Taniguchi, Ph.D., professor emeritus and project professor, department of molecular immunology, Institute of Industrial Science, The University of Tokyo, The Regulation of Immune Responses by Self-derived Molecules

4:15 p.m.: Falk Nimmerjahn, Ph.D., professor, department of biology, University of Erlangen-Nuremberg, Novel Humanized Mouse Models to Understand and Modulate Human IgG Activity

4:45 p.m.: Max D. Cooper, M.D., professor, department of pathology and laboratory medicine, professor, Emory Vaccine Center, investigator, Emory Center for AIDS Research, Emory University School of Medicine, Evolution of Adaptive Immunity

5:15 p.m.: Jeffrey V. Ravetch, M.D., Ph.D., Theresa and Eugene M. Lang Professor, Leonard Wagner Laboratory of Molecular Genetics and Immunology, The Rockefeller University, Closing Remarks

Lydia Finley, Ph.D., Postdoctoral Fellow, Memorial Sloan Kettering Cancer Center

Leonidas Tsiokas, Ph.D., professor, department of cell biology, John S. Gammil Endowed Chair in Polycystic Kidney Disease, Warren Medical Research Institute, University of Oklahoma Health Sciences Center